Publikationen der Klinik für Strahlentherapie und Onkologie

Hier finden Sie die Publikationen der Klinik für Strahlentherapie und Onkologie der letzten Jahre.

Publikationen 2019

Diefenhardt M, Hofheinz RD, Martin D, Beissbarth T, Arnold D, Hartmann A, von der Grün J, Grützmann R, Liersch T, Ströbel P, Grabenbauer GG,  Rieger M, Fietkau R, Graeven U, Weitz J, Folprecht G, Ghadimi M, Rödel F, Rödel C, Fokas E. Leukocytosis and neutrophilia as independent prognostic immunological biomarkers for clinical outcome in the CAO/ARO/AIO-04 randomized phase 3 rectal cancer trial. Int J Cancer 2019; epub ahead of print. (Pubmed-Link)

Eder T, Hess AK, Konschak R, Stromberger C, Jöhrens K, Fleischer V, Hummel M, Balermpas P, von der Grün J, Linge A, Lohaus F, Krause M, Baumann M, Stuschke M, Zips D, Grosu A, Abdollahi A, Debus J, Belka C, Pigorsch S, Combs S, Budach V, Tinhofer I. Interference of tumor mutational burden with outcome of patients with head and neck cancer treated with definitive chemoradiation: A multicenter retrospective study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG). Eur. J. Cancer 2019; accepted. (Pubmed-Link).

Fokas E, Allgäuer M, Polat B, Klautke G, Grabenbauer GG, Fietkau R, Kuhnt T, Staib L, Brunner T, Grosu AL, Schmiegel W,  Jacobasch L, Weitz J, Folprecht G, Schlenka-Lange A, Flentje M, Germer CT, Grützmann R, Schwarzbach M, Paolucci V, Bechstein WO, Friede T, Ghadimi M, Hofheinz RD, Rödel C, German Rectal Cancer Study Group. Randomized Phase II Trial on Chemoradiotherapy plus Induction or Consolidation Chemotherapy as Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer: CAO/ARO/AIO-12. J Clin Oncol 2019; epub ahead of print (Pubmed-Link)

Gani C, Gani N, Zschaeck S, Eberle F, Schaeffeler N, Hehr T, Berger B, Fischer SG, Claßen J, Zipfel S, Rödel C, Teufel M, Zips D. Organ Preservation in Rectal Cancer: The Patients' Perspective .Front Oncol 2019;10;9:318. (Pubmed-Link).

Hess AK, Jöhrens K, Zakarneh A, Balermpas P, von der Grün J, Rödel C, Weichert W, Hummel M, Keilholz U, Budach V, Tinhofer I.  Characterization of the Tumor Immune Micromilieu and its Interference with Outcome After Concurrent Chemoradiation in Patients with Oropharyngeal Carcinomas. Oncoimmunology 2019; accepted. (Pubmed-Link)

Hess J, Unger K, Maihoefer C, Schüttrumpf L, Wintergerst L, Heider T, Weber P, Marschner S, Braselmann H, Samaga D, Kuger S, Pflugradt U, Baumeister P, Walch A, Woischke C, Kirchner T, Werner M, Werner K, Baumann M, Budach V, Combs SE, Debus J, Grosu AL, Krause M, Linge A, Rödel C, Stuschke M, Zips D, Zitzelsberger HF, Ganswindt U, Henke M, Belka C. A Five-MicroRNA Signature Predicts Survival and Disease Control of Patients with Head and Neck Cancer Negative for HPV-infection. Clin Cancer Res 2019;25:1505-1516. (Pubmed-Link)

Hoey C, Ahmed M, Fotouhi Ghiam A, Vesprini D, Huang X, Commisso K, Commisso A, Ray J, Fokas E, Loblaw DA, He HH, Liu SK. Circulating miRNAs as non-invasive biomarkers to predict aggressive prostate cancer after radical prostatectomy. J Transl Med 2019;17:173. (Pubmed-Link).

Klement RJ, Abbasi-Senger N, Adebahr S, Alheid H ,Allgaeuer M, Becker G, Blanck O, Boda-Heggemann J, Brunner T, Duma M, Eble MJ, Ernst I, Gerum S, Habermehl D, Hass P, Henkenberens C, Hildebrandt G, Imhoff D, Kahl H, Klass ND, Krempien R, Lewitzki V, Lohaus F, Ostheimer C, Papachristofilou A, Petersen C, Rieber J, Schneider T, Schrade E, Semrau R, Wachter S, Wittig A, Guckenberger M, Andratschk A. The impact of local control on overall survival after stereotactic body radiotherapy for liver and lung metastases from colorectal cancer: a combined analysis of 388 patients with 500 metastases. BMC Cancer 2019;19:173. (Pubmed-Link)

Lang BM, Balermpas P, Bauer A, Blum A, Brölsch GF, Dirschka T, Follmann M, Frank J, Frerich B, Fritz K, Hauschild A, Heindl LM, Howaldt HP, Ihrler S, Kakkassery V, Klumpp B, Krause-Bergmann A, Löser C, Meissner M, Sachse MM, Schlaak M, Schön MP, Tischendorf L, Tronnier M, Vordermark D, Welzel J, Weichenthal M, Wiegand S, Kaufmann R, Grabbe S. S2k Guidelines for Cutaneous Basal Cell Carcinoma - Part 1: Epidemiology, Genetics and Diagnosis . J Dtsch Dermatol Ges 2019;17:94-103. (Pubmed-Link)

Linder B, Wehle A, Bonn F, Hehlgans S, Dikic I, Rödel F. Seifert V, Kögel D. Arsenic Trioxid and (-)-Gossypol synergistically target glioma stem-like cells via Inhibition of Hedgehog and Notch signaling. Cancers 2019:11:350. (Pubmed-Link)

Martin D, Rödel C, Fokas E. Chemoradiotherapy for anal cancer: are we as good as we think? Strahlenther Onkol 2019;195:369-373. (Pubmed-Link)

Müller-Längle A, Lutz H, Hehlgans S, Rödel F, Rau K, Laube B. NMDA Receptor-mediated signaling pathways enhance radiation resistance, survival and migration in glioblastoma cells - a potential target for adjuvant radiotherapy. Cancers 2019;11:E50. (Pubmed-Link)

Montero A, Sabater S, Rödel F, Gaipl US, Ott OJ, Seegenschmiedt MH, Arenas M. Is it time to redefine the role of low-dose radiotherapy for benign disease? Ann Rheum Dis 2018 Comment, epub ahead of print. (Pubmed-Link)

Ott OJ, Micke O, Mücke R, Niewald M, Rödel F, Schäfer U, Seegenschmiedt MH, Arenas M, Frey B, Gaipl US. Low-dose radiotherapy: Mayday, mayday, we've been hit! Strahlenther Onkol 2018; Editorial, epub ahead of print. (Pubmed-Link).

Raab M, Sanhaji M, Zhou S, Rödel F, El-Balat A, Becker S, Strebhardt K. Blocking mitotic exit of ovarian cancer cells by pharmaceutical inhibition of the Anaphase-Promoting Complex reduces chromosomal instability. Neoplasia 2019;21:363-375. (Pubmed-Link)

Rödel F, Martin D, Balermpas P, Wieland U, Winkelmann R, Riekmann T, Falk S, Rödel C, Fokas E. Modulation of radiation sensitivity and antitumor immunity by viral pathogenic factors: Implications for radio-immunotherapy. Biochim Biophys Acta Rev Cancer  2019;1871:126-137. (Pubmed-Link)

Stera S, Balermpas P, Blanck O, Wolff R, Wurster S, Baumann R, Szücs M, Loutfi-Krauss B, Wilhelm MS, Seifert V, Rades D, Rödel C, Dunst J, Hildebrandtg,  Arnold, A, Meissner M, Kähler, KC. Stereotactic radiosurgery combined with immune checkpoint inhibitors or kinase inhibitors for patients with multiple brain metastases of malignant melanoma. Melanoma Research2019;29:187-195. (Pubmed-Link)

Von der Grün J, Köhn J, Loutfi-Krauss B, Blanck O, Rödel C, Balermpas P. Second infield re-irradiation with a resulting cumulative equivalent dose (EQD2max ) of >180 Gy for patients with recurrent head and neck cancer. Head Neck 2019;41:E48-E54. (Pubmed-Link)

Von der Grün J, Winkelmann R, Meissner  M, Wieland U, Silling S, Martin D, Fokas E, Rödel C, Rödel F, Balermpas P. Merkel cell polyoma viral load and CD8+ lymphocyte infiltration predict overall survival in patients with Merkel cell carcinoma. Front Oncol 2019;9:20. (Pubmed-Link)

Von der Grün J, Rödel F, Fokas E, Guckenberger M, Rödel C, Brandts C, Balermpas P. Targeted therapies and immune-checkpoint inhibition in head and neck squamous cell carcinoma: Where do we stand and where to go. Cancers 2019;11:472. (Pubmed-Link)

Voss M, Franz K, Steinbach JP, Fokas E, Forster MT, Filipski K, Hattingen E, Wagner M, Breuer S. Contrast enhancing spots as a new pattern of late onset pseudoprogression in glioma patients. J Neurooncol 2019;142:161-169. (Pubmed-Link)

Wunderlich R, Rühle P, Deloch L, Rödel F, Fietkau R, Gaipl U, Frey B. Ionizing radiation reduces the capacity of activated macrophages to induce T-cell proliferation, but does not trigger dendritic cell-mediated non targeted effects. Int J Radiation Biol 2019;95:33-43. (Pubm